(Q40662825)

English

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri

scientific article published on 20 May 2016

Statements

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri (English)
Anna-Maria Fink
Christian Maurer
Elisabeth Lange
Hubert Köppler
Martin Sökler
Georg Köchling
Christoph Plöger
Michael Gregor
Torben Plesner
Kirsten Fischer
Harmut Döhner
Wolfram Klapper
Karl-Anton Kreuzer
Sebastian Böttcher
international group of investigators
German CLL Study Group (GCLLSG)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit